TRIL - Trillium Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.8600
+0.0900 (+5.08%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.7700
Open1.7300
Bid0.00 x 500
Ask0.00 x 2000
Day's Range1.5100 - 1.9600
52 Week Range1.5100 - 9.1630
Volume491,580
Avg. Volume136,031
Market Cap27.07M
Beta (3Y Monthly)3.57
PE Ratio (TTM)N/A
EPS (TTM)-2.55
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.02
Trade prices are not sourced from all markets
  • GlobeNewswire14 days ago

    Trillium Therapeutics Provides Update on its Intratumoral TTI-621 Program at the American Society of Hematology 60th Annual Meeting

    Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that new clinical data from the ongoing intratumoral trial of its CD47-blocking agent, TTI-621 (SIRPa-IgG1 Fc), were presented at the American Society of Hematology 60th Annual Meeting, December 1-4, in San Diego, California. “These results build upon the clinical data reported at the EORTC Cutaneous Lymphoma Task Force meeting in September and provide further evidence that intratumoral TTI-621 is well tolerated and biologically active in patients with cutaneous T-cell lymphoma,” said Dr. Niclas Stiernholm, president and CEO of Trillium Therapeutics.

  • GlobeNewswire3 months ago

    Trillium Therapeutics to Provide Update on TTI-621 Clinical Programs at Two Scientific Conferences

    Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it will be providing updates on its two clinical trials with TTI-621, a dual function SIRPaFc IgG1 decoy receptor that targets CD47, at two upcoming scientific conferences. As previously announced, the presentations will be made on September 28 at the European Organisation for Research and Treatment of Cancer, Cutaneous Lymphoma Task Force (EORTC CLTF) meeting in St. Gallen, Switzerland and the 16th Annual Discovery on Target conference in Boston, MA. The presentation at the EORTC CLTF meeting will provide an update on the safety and efficacy of the ongoing multicenter, open-label phase 1 intratumoral trial of TTI-621 in 23 patients with relapsed/refractory mycosis fungoides/Sézary syndrome, 20 of whom only received induction therapy consisting of 1-6 injections over 2 weeks.

  • GlobeNewswire3 months ago

    Trillium Therapeutics to Present at Upcoming Investor Conferences

    TORONTO, Sept. 27, 2018-- Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled ...

  • Marketwired10 months ago

    Trillium Therapeutics to Present at Investor and Scientific Conferences in the First Quarter

    Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on ...

  • ACCESSWIRE11 months ago

    Blog Exposure - Trillium Announces Changes to Senior Management Team

    LONDON, UK / ACCESSWIRE / January 19, 2018 / Active-Investors.com has just released a free research report on Trillium Therapeutics Inc. (NASDAQ: TRIL ) ("Trillium"). If you want access to this ...

  • Marketwired11 months ago

    Trillium Therapeutics Enhances Senior Management Team to Support Further Clinical Development of TTI-621

    Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the following key additions to its leadership team: